Pyxis Oncology, Inc., was incorporated in Delaware on June 11, 2018. The company is a clinical-stage oncology company advancing a development strategy focused on addressing the unmet medical needs of patients with solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC).
